Thousands tracked in psoriasis drug safety registry

NCT ID NCT02786186

Completed Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed over 2,300 adults with moderate to severe plaque psoriasis to see how safe and effective secukinumab is in everyday medical practice. Researchers recorded side effects and how well the drug cleared skin symptoms. The goal was to gather real-world evidence, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS

Contacts and locations

Locations

Novartis Investigative Site

Edmonton, Alberta, T6G 1C3, Canada
Novartis Investigative Site

Nanaimo, British Columbia, V9T 1W1, Canada
Novartis Investigative Site

Surrey, British Columbia, V3R 6A7, Canada
Novartis Investigative Site

Vancouver, British Columbia, V5Z 1M9, Canada
Novartis Investigative Site

Brandon, Manitoba, R7A 0L5, Canada
Novartis Investigative Site

Winnepeg, Manitoba, R3M1Z9, Canada
Novartis Investigative Site

Winnipeg, Manitoba, R3C 0N2, Canada
Novartis Investigative Site

Fredericton, New Brunswick, E3B 1G9, Canada
Novartis Investigative Site

St. John's, Newfoundland and Labrador, A1A 4Y3, Canada
Novartis Investigative Site

St. John's, Newfoundland and Labrador, A1C 2H5, Canada
Novartis Investigative Site

Hamilton, Ontario, L8N 3Z5, Canada
Novartis Investigative Site

London, Ontario, N6A 3H7, Canada
Novartis Investigative Site

Nepean, Ontario, K2G 6E2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.